Media Highlights
Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma
December 09, 2024
Sylvester hematologist, Dr. Juan P. Alderuccio, is highlighted in this MSN article for a clinical trial showing that a combination of loncastuximab tesirine and rituximab produced strong response rates—including 66.7% complete responses—in high-risk relapsed or refractory follicular lymphoma patients.
Tags: Juan Alderuccio, Sylvester, Sylvester Comprehensive Cancer Center
